Ординатура / Офтальмология / Английские материалы / Retinal and Choroidal Angiogenesis_Penn_2008

evaluate anecortave acetate delivered via posterior juxtascleral deposition in patients with dry AMD who are at risk for converting to exudative AMD.

The intense progress made over the last decade in discovering and developing novel treatments for retinal diseases has been the result of extensive collaborations between academia, private practice, governmental agencies and private industry. Because of the natural history of most posterior segment diseases, the clinical trials necessary to achieve regulatory approval are large, lengthy, and very expensive. Cooperation between all aspects of the retina community will need to continue, if we are to move prospective treatments forward as fast as possible. Moreover, for those students in the process of determining their field of interest, the science and medicine of retinal disease are just now really beginning to blossom, providing unique employment prospects as well as the opportunity to have a direct impact on the quality of life of a rapidly growing portion of the population.

REFERENCES

1.J. Folkman, Tumor angiogenesis: therapeutic implications, N. Engl. J. Med. 285 (21), 1182-1186 (1971).

2.W. Smith, J. Assink, R. Klein, P. Mitchell, C. C. Klaver, B. E. Klein, A. Hofman, S. Jensen, J. J. Wang and P. T. de Jong, Risk factors for age-related macular degeneration: Pooled findings from three continents, Ophthalmology 108 (4), 697-704 (2001).

3.Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Macular Photocoagulation Study Group, Arch. Ophthalmol. 111 (9), 1189-1199 (1993).

4.F. L. Ferris, 3rd, Senile macular degeneration: review of epidemiologic features,

American Journal of Epidemiology 118 (2), 132-151 (1983).

5.J. J. Weiter, Optics of Laser Irradiation, in: Retina, edited by S. J. Ryan, 1st Edition (Mosby, St Louis, 2001) pp. 499-509.

6.Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial, Arch. Ophthalmol. 101 (9), 1358-1361 (1983).

7.Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group, Ophthalmology 98 (5 Suppl), 766-785 (1991).

8.Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group, Arch. Ophthalmol. 111 (9), 1200-1209 (1993).

9.Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group, Arch. Ophthalmol. 112 (4), 500-509 (1994).

10.Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Macular Photocoagulation Study Group, Arch. Ophthalmol. 112 (4), 480-488 (1994).

11.Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group, Arch. Ophthalmol. 115 (6), 741-747 (1997).

12.S. Schneider, C. M. Greven and W. R. Green, Photocoagulation of well-defined choroidal neovascularization in age-related macular degeneration: clinicopathologic correlation, Retina 18 (3), 242-250 (1998).

13.T. J. Dougherty and S. L. Marcus, Photodynamic therapy, Eur. J. Cancer 28A (10), 1734-1742 (1992).

14.M. J. Kaplan, R. G. Somers, R. H. Greenberg and J. Ackler, Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2), J. Surg. Oncol. 67 (2), 121-125 (1998).

15.E. Ben Hur and A. Orenstein, The endothelium and red blood cells as potential targets in PDT-induced vascular stasis, Int. J. Radiat. Biol. 60 (1-2), 293-301 (1991).

16.Photodynamic therapy with verteporfin for age-related macular degeneration. American Academy of Ophthalmology, Ophthalmology 107 (12), 2314-2317 (2000).

17.R. Haimovici, M. Kramer, J. W. Miller, T. Hasan, T. J. Flotte, K. T. Schomacker and

E.S. Gragoudas, Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye, Curr. Eye Res. 16 (2), 83-90 (1997).

18.L. J. Scott and K. L. Goa, Verteporfin, Drugs Aging 16 (2), 139-146 (2000).

19.Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group, Arch. Ophthalmol. 117 (10), 1329-1345 (1999).

20.N. M. Bressler, Photodynamic therapy of subfoveal choroidal neovascularization in agerelated macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2, Arch. Ophthalmol. 119 (2), 198-207 (2001).

21.Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. CORPORATE AUTHOR: Verteporfin-In-Photodynamic-Therapy-Study-Group, Am. J. Ophthalmol. 131 (5), 541-560 (2001).

22.M. J. Potter, S. M. Szabo and W. W. Li, Comparison of visual acuity outcomes in predominantly classic vs occult lesions in age-related macular degeneration treated with photodynamic therapy, Eye (2006).

23.VIM Study Group. Verteporfin in minimally classic CNV due to AMD (VIM)-two year results from a phase II controlled clinical trial., Invest. Ophthalmol. Vis. Sci. 45 E-2273 (2004).

24.M. Azab, D. S. Boyer, N. M. Bressler, S. B. Bressler, I. Cihelkova, Y. Hao, I. Immonen,

J.I. Lim, U. Menchini, J. Naor, M. J. Potter, A. Reaves, P. J. Rosenfeld, J. S. Slakter,

P.Soucek, H. A. Strong, A. Wenkstern, X. Y. Su and Y. C. Yang, Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial, Arch. Ophthalmol. 123 (4), 448-457 (2005).

25.VER study Group. Verteporfin Early Retreatment (VER) - 12-month results of a phase IIIB controlled clinical trial., Invest. Ophthalmol. Vis. Sci. 45 E-2275 (2004).

26.VALIO study group. Verteporfin with altered (delayed) light in occult (VALIO)-12- month results of a phase II controlled clinical trial., Invest. Ophthalmol. Vis. Sci. 45 E- 2274 (2004).

27.Macular Degeneration Support . FDA approves VisudyneTM therapy for AMD; a major advance in Ophthalmology, http://www.mdsupport.org/library/pdtapprov.html April 12

(2000).

28.Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes, Retina 22 (1), 6-18 (2002).

29.M. Azab, M. Benchaboune, K. J. Blinder, N. M. Bressler, S. B. Bressler, E. S. Gragoudas,

G.E. Fish, Y. Hao, L. Haynes, J. I. Lim, U. Menchini, J. W. Miller, J. Mones, M. J. Potter,

A.Reaves, P. J. Rosenfeld, A. Strong, X. Y. Su, J. S. Slakter, U. Schmidt Erfurth and

J.A. Sorenson, Verteporfin therapy of subfoveal choroidal neovascularization in agerelated macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4, Retina 24 (1), 1-12 (2004).

30.P. J. Rosenfeld, S. D. Schwartz, M. S. Blumenkranz, J. W. Miller, J. A. Haller, J. D. Reimann,

W.L. Greene and N. Shams, Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration, Ophthalmology 112 (6), 1048-1053 (2005).

31.H. Nishiwaki, R. Zeimer, M. F. Goldberg, S. A. D’Anna, S. A. Vinores and R. Grebe, Laser targeted photo-occlusion of rat choroidal neovascularization without collateral damage, Photochem. Photobiol. 75 (2), 149-158 (2002).

32.C. Fenton and C. M. Perry, Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation, Drugs Aging 23 (5), 421-445 (2006).

33.K. J. Blinder, S. Bradley, N. M. Bressler, S. B. Bressler, G. Donati, Y. Hao, C. Ma,

U.Menchini, J. Miller, M. J. Potter, C. Pournaras, A. Reaves, P. J. Rosenfeld, H. A. Strong,

M.Stur, X. Y. Su and G. Virgili, Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1, Am. J. Ophthalmol. 136 (3), 407-418 (2003).

34.K. J. Blinder, M. S. Blumenkranz, N. M. Bressler, S. B. Bressler, G. Donato, H. Lewis,

J.I. Lim, U. Menchini, J. W. Miller, J. M. Mones, M. J. Potter, C. Pournaras, A. Reaves,

P.Rosenfeld, A. P. Schachat, U. Schmidt-Erfurth, M. Sickenberg, L. J. Singerman,

J.S. Slakter, H. A. Strong, G. Virgili and G. A. Williams, Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3, Ophthalmology 110 (4), 667-673 (2003).

35.N. M. Bressler, J. Arnold, M. Benchaboune, M. S. Blumenkranz, G. E. Fish, E. S. Gragoudas,

H.Lewis, U. Schmidt-Erfurth, J. S. Slakter, S. B. Bressler, K. Manos, Y. Hao, L. Hayes,

J.Koester, A. Reaves and H. A. Strong, Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes-TAP report No. 3, Arch. Ophthalmol. 120 (11), 1443-1454 (2002).

36.N. M. Bressler, Verteporfin therapy of subfoveal choroidal neovascularization in agerelated macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2, Am. J. Ophthalmol. 133 (1), 168-169 (2002).

37.N. M. Bressler, S. B. Bressler, L. A. Haynes, Y. Hao, P. K. Kaiser, J. W. Miller, J. Naor,

M.J. Potter, C. J. Pournaras, A. Reaves, P. J. Rosenfeld, U. Schmidt-Erfurth, J. S. Slakter,

A.Strong and S. Vannier, Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of

2 randomized clinical trials: TAP Report No. 7, Arch. Ophthalmol. 123 (9), 1283-1285 (2005).

38.S. Grisanti, O. Tatar, S. Canbek, B. A. Lafaut, F. Gelisken, W. Inhoffen, P. Szurman,

S.Aisenbrey, J. Oficjalska Mlynczak and K. U. Bartz Schmidt, Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy, Am. J. Ophthalmol. 137 (5), 914-923 (2004).

39.S. Michels and U. Schmidt-Erfurth, Sequence of early vascular events after photodynamic therapy, Invest. Ophthalmol. Vis. Sci. 44 (5), 2147-2154 (2003).

40.U. Schmidt-Erfurth, U. Schlotzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf and

G.O. Naumann, Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor, Invest. Ophthalmol. Vis. Sci. 44 (10), 4473-4480 (2003).

41.R. F. Spaide, J. Sorenson and L. Maranan, Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization, Ophthalmology 112 (2), 301-304 (2005).

42.A. Van de Moere, S. S. Sandhu, R. Kak, K. W. Mitchell and S. J. Talks, Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin, Ophthalmology 112 (11), 1896-1903 (2005).

43.E. Rechtman, R. P. Danis, L. M. Pratt and A. Harris, Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration, Br. J.Ophthalmol. 88 (3), 344-347 (2004).

44.W. M. Chan, T. Y. Lai, A. L. Wong, J. P. Tong, D. T. Liu and D. S. Lam, Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study, Br. J.Ophthalmol. 90 (3), 337-341 (2006).

45.A. Tewari, G. K. Shah, M. S. Dhalla and J. B. Shepherd, Combination photodynamic therapy and juxtascleral triamcinolone acetonide for the treatment of a peripapillary choroidal neovascular membrane associated with papilloedema, Br. J.Ophthalmol. 90 (10), 1323-1324 (2006).

46.J. S. Heier, D. S. Boyer, T. A. Ciulla, P. J. Ferrone, J. M. Jumper, R. C. Gentile, D. Kotlovker, C. Y. Chung and R. Y. Kim, Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study, Arch. Ophthalmol. 124 (11), 1532-1542 (2006).

47.R. W. Flower, Optimizing treatment of choroidal neovascularization feeder vessels associated with age-related macular degeneration, Am. J. Ophthalmol. 134 (2), 228-239 (2002).

48.F. Shiraga, Y. Ojima, T. Matsuo, I. Takasu and N. Matsuo, Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration, Ophthalmology 105 (4), 662-669 (1998).

49.G. Staurenghi, N. Orzalesi, A. La Capria and M. Aschero, Laser treatment of feeder vessels in subfoveal choroidal neovascular membranes: a revisitation using dynamic indocyanine green angiography, Ophthalmology 105 (12), 2297-2305 (1998).

50.S. Piermarocchi, G. Lo Giudice, M. Sartore, F. Friede, T. Segato, E. Pilotto and E. Midena, Photodynamic therapy increases the eligibility for feeder vessel treatment of choroidal neovascularization caused by age-related macular degeneration, Am. J. Ophthalmol. 133 (4), 572-575 (2002).

51.W. P. Beetham, L. M. Aiello, M. C. Balodimos and L. Koncz, Ruby laser photocoagulation of early diabetic neovascular retinopathy. Preliminary report of a long-term controlled study, Arch. Ophthalmol. 83 (3), 261-272 (1970).

52.Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group, Am. J. Ophthalmol. 81 (4), 383-396 (1976).

53.R. Klein, B. E. Klein and S. E. Moss, Epidemiology of proliferative diabetic retinopathy, Diabetes Care 15 (12), 1875-1891 (1992).

54.T. Ho, W. E. Smiddy and H. W. Flynn, Jr., Vitrectomy in the management of diabetic eye disease, Surv. Ophthalmol. 37 (3), 190-202 (1992).

55.P. G. Arrigg and J. Cavallerano, The role of vitrectomy for diabetic retinopathy, Journal of the American Optometric Association 69 (11), 733-740 (1998).

56.Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group, Ophthalmology 95 (10), 1307-1320 (1988).

57.Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5, Arch. Ophthalmol. 108 (7), 958-964 (1990).

58.S. Sharma, H. Hollands, G. C. Brown, M. M. Brown, G. K. Shah and S. M. Sharma, The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy, Current Opinion in Ophthalmology 12 (3), 230-234 (2001).

59.J. J. Weiter and R. Zuckerman, The influence of the photoreceptor-RPE complex on the inner retina. An explanation for the beneficial effects of photocoagulation, Ophthalmology 87 (11), 1133-1139 (1980).

60.M. L. Wolbarsht and M. B. Landers, 3rd, The rationale of photocoagulation therapy for proliferative diabetic retinopathy: a review and a model, Ophthalmic Surgery 11 (4), 235-245 (1980).

61.E. Stefansson, D. L. Hatchell, B. L. Fisher, F. S. Sutherland and R. Machemer, Panretinal photocoagulation and retinal oxygenation in normal and diabetic cats, Am. J. Ophthalmol. 101 (6), 657-664 (1986).

62.M. Matsumoto, N. Yoshimura and Y. Honda, Increased production of transforming growth factor-beta 2 from cultured human retinal pigment epithelial cells by photocoagulation, Invest. Ophthalmol. Vis. Sci. 35 (13), 4245-4252 (1994).

63.N. Yoshimura, M. Matsumoto, H. Shimizu, M. Mandai, Y. Hata and T. Ishibashi, Photocoagulated human retinal pigment epithelial cells produce an inhibitor of vascular endothelial cell proliferation, Invest. Ophthalmol. Vis. Sci. 36 (8), 1686-1691 (1995).

64.N. Ogata, J. Tombran-Tink, N. Jo, D. Mrazek and M. Matsumura, Upregulation of pigment epithelium-derived factor after laser photocoagulation, Am. J. Ophthalmol. 132 (3), 427-429 (2001).

65.L. P. Aiello, R. L. Avery, P. G. Arrigg, B. A. Keyt, H. D. Jampel, S. T. Shah, L. R. Pasquale,

H.Thieme, M. A. Iwamoto, J. E. Park and et al., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, N. Engl.

J.Med. 331 (22), 1480-1487 (1994).

66.K. Shinoda, S. Ishida, S. Kawashima, T. Wakabayashi, M. Uchita, T. Matsuzaki,

M.Takayama, K. Shinmura and M. Yamada, Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy, Curr. Eye Res. 21 (2), 655-661 (2000).

67.P. L. Lip, F. Belgore, A. D. Blann, M. W. Hope-Ross, J. M. Gibson and G. Y. Lip, Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment, Invest. Ophthalmol. Vis. Sci. 41 (8), 2115-2119 (2000).

68.N. Ferrara and T. Davis-Smyth, The biology of vascular endothelial growth factor, Endocr. Rev. 18 (1), 4-25 (1997).

69.C. Wiesmann, G. Fuh, H. W. Christinger, C. Eigenbrot, J. A. Wells and A. M. de Vos, Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor, Cell 91 (5), 695-704 (1997).

70.D. W. Leung, G. Cachianes, W. J. Kuang, D. V. Goeddel and N. Ferrara, Vascular endothelial growth factor is a secreted angiogenic mitogen, Science 246 (4935), 1306-1309 (1989).

71.P. J. Keck, S. D. Hauser, G. Krivi, K. Sanzo, T. Warren, J. Feder and D. T. Connolly, Vascular permeability factor, an endothelial cell mitogen related to PDGF, Science 246 (4935), 1309-1312 (1989).

72.D. Hanahan, Signaling vascular morphogenesis and maintenance, Science 277 (5322), 48-50 (1997).

73.G. D. Yancopoulos, S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand and J. Holash, Vascular-specific growth factors and blood vessel formation, Nature 407 (6801), 242-248 (2000).

74.N. Ferrara, H. P. Gerber and J. LeCouter, The biology of VEGF and its receptors, Nat. Med. 9 (6), 669-676 (2003).

75.J. Stone, A. Itin, T. Alon, J. Pe’er, H. Gnessin, T. Chan-Ling and E. Keshet, Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia, J. Neurosci. 15 (7 Pt 1), 4738-4747 (1995).

76.D. T. Shima, A. P. Adamis, N. Ferrara, K. T. Yeo, T. K. Yeo, R. Allende, J. Folkman and

P.A. D’Amore, Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen, Mol. Med. 1 (2), 182-193 (1995).

77.M. E. Hartnett, A. Lappas, D. Darland, J. R. McColm, S. Lovejoy and P. A. D’Amore, Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism, Exp. Eye Res. 77 (5), 593-599 (2003).

78.L. P. Aiello, E. A. Pierce, E. D. Foley, H. Takagi, H. Chen, L. Riddle, N. Ferrara,

G.L. King and L. E. Smith, Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins, Proc. Natl. Acad. Sci. USA 92 (23), 10457-10461 (1995).

79.J. W. Miller, A. P. Adamis, D. T. Shima, P. A. D’Amore, R. S. Moulton, M. S. O’Reilly,

J.Folkman, H. F. Dvorak, L. F. Brown, B. Berse and et al., Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model, Am. J. Pathol. 145 (3), 574-584 (1994).

80.M. J. Tolentino, J. W. Miller, E. S. Gragoudas, K. Chatzistefanou, N. Ferrara and

A.P. Adamis, Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate, Arch. Ophthalmol. 114 (8), 964-970 (1996).

81.A. P. Adamis, D. T. Shima, M. J. Tolentino, E. S. Gragoudas, N. Ferrara, J. Folkman,

P.A. D’Amore and J. W. Miller, Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate, Arch. Ophthalmol. 114 (1), 66-71 (1996).

82.X. Q. Werdich, G. W. McCollum, V. S. Rajaratnam and J. S. Penn, Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy, Exp. Eye Res. 79 (5), 623-630 (2004).

83.A. S. Unsoeld, B. Junker, R. Mazitschek, G. Martin, L. L. Hansen, A. Giannis and

H.T. Agostini, Local injection of receptor tyrosine kinase inhibitor MAE 87 reduces retinal neovascularization in mice, Mol. Vis. 10 468-475 (2004).

84.W. Y. Shen, M. J. Yu, C. J. Barry, I. J. Constable and P. E. Rakoczy, Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat, Br. J. Ophthalmol. 82 (9), 1063-1071 (1998).

85.N. Kwak, N. Okamoto, J. M. Wood and P. A. Campochiaro, VEGF is major stimulator in model of choroidal neovascularization, Invest. Ophthalmol. Vis. Sci. 41 (10), 3158-3164 (2000).

86.M. G. Krzystolik, M. A. Afshari, A. P. Adamis, J. Gaudreault, E. S. Gragoudas,

N.A. Michaud, W. Li, E. Connolly, C. A. O’Neill and J. W. Miller, Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment, Arch. Ophthalmol. 120 (3), 338-346 (2002).

87.G. A. Lutty, D. S. McLeod, C. Merges, A. Diggs and J. Plouet, Localization of vascular endothelial growth factor in human retina and choroid, Arch. Ophthalmol. 114 (8), 971-977 (1996).

88.Y. S. Chen, S. F. Hackett, C. L. Schoenfeld, M. A. Vinores, S. A. Vinores and

P.A. Campochiaro, Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes, Br. J. Ophthalmol. 81 (10), 919-926 (1997).

89.A. N. Witmer, H. G. Blaauwgeers, H. A. Weich, K. Alitalo, G. F. Vrensen and

R.O. Schlingemann, Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey, Invest. Ophthalmol. Vis. Sci. 43 (3), 849-857 (2002).

90.A. Kvanta, P. V. Algvere, L. Berglin and S. Seregard, Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor, Invest. Ophthalmol. Vis. Sci. 37 (9), 1929-1934 (1996).

91.E. S. Gragoudas, A. P. Adamis, E. T. Cunningham, Jr., M. Feinsod and D. R. Guyer, Pegaptanib for neovascular age-related macular degeneration, N. Engl. J. Med. 351 (27), 2805-2816 (2004).

92.Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration, Retina 22 (2), 143-152 (2002).

93.L. A. Sorbera, P. A. Leeson and M. Bayes, Ranibizumab. Treatment of Age-Related Macular Degeneration Humanized Monoclonal Anti-Vegf Antibody Angiogenesis Inhibitor, Drugs of the Future 28 (6), 541-545 (2003).

94.Y. Saishin, K. Takahashi, R. Lima e Silva, D. Hylton, J. S. Rudge, S. J. Wiegand and

P.A. Campochiaro, VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier, J. Cell. Physiol. 195 (2), 241-248 (2003).

95.S. Ishida, T. Usui, K. Yamashiro, Y. Kaji, E. Ahmed, K. G. Carrasquillo, S. Amano,

T.Hida, Y. Oguchi and A. P. Adamis, VEGF164 is proinflammatory in the diabetic retina, Invest. Ophthalmol. Vis. Sci. 44 (5), 2155-2162 (2003).

96.S. Ishida, T. Usui, K. Yamashiro, Y. Kaji, S. Amano, Y. Ogura, T. Hida, Y. Oguchi,

J.Ambati, J. W. Miller, E. S. Gragoudas, Y. S. Ng, P. A. D’Amore, D. T. Shima and

A.P. Adamis, VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization, J. Exp. Med. 198 (3), 483-489 (2003).

97.Y. Chen, C. Wiesmann, G. Fuh, B. Li, H. W. Christinger, P. McKay, A. M. de Vos and

H.B. Lowman, Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen, J. Mol. Biol. 293 (4), 865-881 (1999).

98.E. T. Cunningham, Jr., A. P. Adamis, M. Altaweel, L. P. Aiello, N. M. Bressler,

D.J. D’Amico, M. Goldbaum, D. R. Guyer, B. Katz, M. Patel and S. D. Schwartz,

Aphase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema, Ophthalmology 112 (10), 1747-1757 (2005).

99.M. I. Dorrell, E. Aguilar, L. Scheppke, F. H. Barnett and M. Friedlander, Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis, Proc. Natl. Acad. Sci. USA 104 (3), 967-972 (2007).

100.L. Cao, X. Jiao, D. S. Zuzga, Y. Liu, D. M. Fong, D. Young and M. J. During, VEGF links hippocampal activity with neurogenesis, learning and memory, Nat. Genet. 36 (8), 827-835 (2004).

101.M. Azzouz, G. S. Ralph, E. Storkebaum, L. E. Walmsley, K. A. Mitrophanous,

S.M. Kingsman, P. Carmeliet and N. D. Mazarakis, VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model, Nature 429 (6990), 413-417 (2004).

102.FDA, FDA Approves New Drug Treatment for Age-Related Macular Degeneration, http://www.fda.gov/bbs/topics/news/2004/new01146.html, December 20, 2004.

103.Y. Tian, N. Adya, S. Wagner, C. Z. Giam, M. R. Green and A. D. Ellington, Dissecting protein:protein interactions between transcription factors with an RNA aptamer, Rna 1 (3), 317-326 (1995).

104.F. L. Ferris, 3rd, A new treatment for ocular neovascularization, N. Engl. J.Med. 351 (27), 2863-2865 (2004).

105.S. L. Fine, D. F. Martin and P. Kirkpatrick, Pegaptanib sodium, Nat. Rev. Drug Discov. 4 (3), 187-188 (2005).

106.P. J. Rosenfeld, D. M. Brown, J. S. Heier, D. S. Boyer, P. K. Kaiser, C. Y. Chung and

R.Y. Kim, Ranibizumab for neovascular age-related macular degeneration, N. Engl.

J.Med. 355 (14), 1419-1431 (2006).

107.N. Ferrara, L. Damico, N. Shams, H. Lowman and R. Kim, Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration, Retina 26 (8), 859-870 (2006).

108.P. J. Rosenfeld, R. M. Rich and G. A. Lalwani, Ranibizumab: Phase III clinical trial results, Ophthalmology clinics of North America 19 (3), 361-372 (2006).

109.J. Gaudreault, D. Fei, J. Rusit, P. Suboc and V. Shiu, Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration, Invest. Ophthalmol. Vis. Sci. 46 (2), 726-733 (2005).

110.D. W. Chun, J. S. Heier, T. M. Topping, J. S. Duker and J. M. Bankert, A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema, Ophthalmology 113 (10), 1706-1712 (2006).

111.D. M. Brown, P. K. Kaiser, M. Michels, G. Soubrane, J. S. Heier, R. Y. Kim, J. P. Sy and S. Schneider, Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N. Engl. J. Med. 355 (14), 1432-1444 (2006).

112.P. J. Rosenfeld, J. S. Heier, G. Hantsbarger and N. Shams, Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration, Ophthalmology 113 (4), 632 e631 (2006).

113.Q. D. Nguyen, S. Tatlipinar, S. M. Shah, J. A. Haller, E. Quinlan, J. Sung, I. ZimmerGaller, D. V. Do and P. A. Campochiaro, Vascular endothelial growth factor is a critical stimulus for diabetic macular edema, Am. J. Ophthalmol. 142 (6), 961-969 (2006).

114.H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim,

J.Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross and F. Kabbinavar, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N. Engl. J. Med. 350 (23), 2335-2342 (2004).

115.N. Ferrara, K. J. Hillan, H. P. Gerber and W. Novotny, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nat. Rev. Drug Discov. 3 (5), 391-400 (2004).

116.K. J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H. S. Phillips and N. Ferrara, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature 362 (6423), 841-844 (1993).

117.L. G. Presta, H. Chen, S. J. O’Connor, V. Chisholm, Y. G. Meng, L. Krummen,

M.Winkler and N. Ferrara, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res. 57 (20), 4593-4599 (1997).

118.J. Mordenti, R. A. Cuthbertson, N. Ferrara, K. Thomsen, L. Berleau, V. Licko, P. C. Allen,

C.R. Valverde, Y. G. Meng, D. T. Fei, K. M. Fourre and A. M. Ryan, Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled fulllength and Fab antibodies in rhesus monkeys following intravitreal administration, Toxicol. Pathol. 27 (5), 536-544 (1999).

119.J. S. Heier, A. N. Antoszyk, P. R. Pavan, S. R. Leff, P. J. Rosenfeld, T. A. Ciulla,

R.F. Dreyer, R. C. Gentile, J. P. Sy, G. Hantsbarger and N. Shams, Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study, Ophthalmology 113 (4), 642 e641-644 (2006).

120.S. R. Miller, Lucentis (Under Study) May Reverse Effects Of Eye Disorder, Newsletter from the Macular Degeneration Foundation, Inc. 33 (2005).

121.Genentech-Press-Release, Preliminary Results from a Phase IIIb Study Showed Patients with Wet AMD Treated with Lucentis Quarterly Experienced a 16-Letter Benefit over the Control Group at One Year, http://www.gene.com/gene/news/press-releases/display. do?method=detail&id=9747 June 02 (2006).

122.S. Michels, P. J. Rosenfeld, C. A. Puliafito, E. N. Marcus and A. S. Venkatraman, Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study, Ophthalmology 112 (6), 1035-1047 (2005).

123.H. Barron, Important Drug Warning, http://www.fda.gov/medwatch/SAFETY/2004/ Avastin_deardoc_mod.pdf (2004).

124.H. Barron, Important Drug Warning, http://www.fda.gov/medwatch/SAFETY/2005/ Avastin_dearhcp.pdf (2005).

125.Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer, Cancer Treat. Rev. 30 (8), 715-717 (2004).

126.Medscape, Treating AMD With VEGF Inhibition: An Expert Interview With Peter

K.Kaiser, MD, http://www.medscape.com/viewarticle/509975 August 05 (2005).

127.P. J. Rosenfeld, A. E. Fung and C. A. Puliafito, Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion, Ophthalmic Surg. Lasers Imaging 36 (4), 336-339 (2005).

128.P. J. Rosenfeld, A. A. Moshfeghi and C. A. Puliafito, Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular agerelated macular degeneration, Ophthalmic Surg. Lasers Imaging 36 (4), 331-335 (2005).

129.L. Feiner, E. E. Barr, Y. B. Shui, N. M. Holekamp and M. A. Brantley, Jr., Safety of intravitreal injection of bevacizumab in rabbit eyes, Retina 26 (8), 882-888 (2006).

130.J. O. Mason, 3rd, M. A. Albert, Jr. and R. Vail, Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema, Retina 26 (3), 356-357 (2006).

131.R. L. Avery, Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment, Retina 26 (3), 352-354 (2006).

132.R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir and M. J. Giust, Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration, Ophthalmology 113 (3), 363-372 e365 (2006).

133.D. Iturralde, R. F. Spaide, C. B. Meyerle, J. M. Klancnik, L. A. Yannuzzi, Y. L. Fisher,

J.Sorenson, J. S. Slakter, K. B. Freund, M. Cooney and H. F. Fine, Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study, Retina 26 (3), 279-284 (2006).

134.R. F. Spaide and Y. L. Fisher, Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage, Retina 26 (3), 275-278 (2006).

135.R. F. Spaide, K. Laud, H. F. Fine, J. M. Klancnik, Jr., C. B. Meyerle, L. A. Yannuzzi,

J.Sorenson, J. Slakter, Y. L. Fisher and M. J. Cooney, Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration, Retina 26 (4), 383-390 (2006).

136.R. K. Maturi, L. A. Bleau and D. L. Wilson, Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment, Retina 26 (3), 270-274 (2006).

137.J. Shahar, R. L. Avery, G. Heilweil, A. Barak, E. Zemel, G. P. Lewis, P. T. Johnson,

S.K. Fisher, I. Perlman and A. Loewenstein, Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin), Retina 26 (3), 262-269 (2006).

138.R. P. Manzano, G. A. Peyman, P. Khan and M. Kivilcim, Testing intravitreal toxicity of bevacizumab (Avastin), Retina 26 (3), 257-261 (2006).

139.F. H. Davidorf, J. G. Mouser and R. J. Derick, Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection, Retina 26 (3), 354-356 (2006).

140.P. Yoganathan, V. A. Deramo, J. C. Lai, R. K. Tibrewala and D. M. Fastenberg, Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration, Retina 26 (9), 994-998 (2006).

141.C. Haritoglou, D. Kook, A. Neubauer, A. Wolf, S. Priglinger, R. Strauss, A. Gandorfer,

M.Ulbig and A. Kampik, Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema, Retina 26 (9), 999-1005 (2006).

142.P. M. Beer, S. J. Wong, A. M. Hammad, N. S. Falk, M. R. O’Malley and S. Khan, Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients, Retina 26 (8), 871-876 (2006).

143.R. Jorge, R. A. Costa, D. Calucci, L. P. Cintra and I. U. Scott, Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study), Retina 26 (9), 1006-1013 (2006).

144.C. Kiss, S. Michels, F. Prager, G. Weigert, W. Geitzenauer and U. Schmidt-Erfurth, Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab, Retina 26 (8), 877-881 (2006).

145.A. Tewari, M. S. Dhalla and R. S. Apte, Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia, Retina 26 (9), 1093-1094 (2006).

146.K. Laud, R. F. Spaide, K. B. Freund, J. Slakter and J. M. Klancnik, Jr., Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab, Retina 26 (8), 960-963 (2006).